Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Gynecologic 1

Conditions

Multiple Myeloma 2Recurrence 1Carcinoma, Ovarian Epithelial 1

Interventions

Specimen Handling 613pembrolizumab 583Magnetic Resonance Spectroscopy 543Carboplatin 430Cyclophosphamide 380Cisplatin 377Biopsy 366Paclitaxel 314Nivolumab 312Gemcitabine 308Radiotherapy 268Bevacizumab 230Dexamethasone 217fludarabine 205Docetaxel 190durvalumab 188venetoclax 187Oxaliplatin 187Rituximab 174Fluorouracil 174atezolizumab 169Pemetrexed 166Capecitabine 162Radiosurgery 160Doxorubicin 160Radiation 156Ipilimumab 144Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Clarithromycin × 90 days × Clear all
NCT04302324 2026-05-20

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
11 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT07341100 2026-05-11

Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting
20 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT02343042 2026-05-04

STOMP

Karyopharm Therapeutics Inc

Phase 1/2 Active not recruiting
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡